Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
7.89
-0.78 (-9.00%)
Aug 15, 2025, 9:53 AM - Market open

Sagimet Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-59.38-45.57-27.88-30.5-24.44-11.37
Upgrade
Loss (Gain) From Sale of Assets
------0.02
Upgrade
Loss (Gain) From Sale of Investments
-1.34-1.25-0.04-0.21--
Upgrade
Stock-Based Compensation
6.155.294.991.881.90.78
Upgrade
Other Operating Activities
0.150.150.140.130.880.12
Upgrade
Change in Accounts Payable
2.12-0.910.122.920.56-0.36
Upgrade
Change in Other Net Operating Assets
-1.93-0.14-1.11.3-0.620.44
Upgrade
Operating Cash Flow
-54.23-42.44-23.77-24.49-21.71-10.42
Upgrade
Sale of Property, Plant & Equipment
-----0.02
Upgrade
Investment in Securities
0.6-61.6812.58-32.01--
Upgrade
Investing Cash Flow
0.6-61.6812.58-32.01-0.02
Upgrade
Issuance of Common Stock
0105.8689.690.010.19-
Upgrade
Other Financing Activities
--1.05-3.52-0.09-1.25-
Upgrade
Financing Cash Flow
0104.8286.17-0.079.7468.89
Upgrade
Net Cash Flow
-53.630.774.98-56.57-11.9758.49
Upgrade
Levered Free Cash Flow
-35.55-29.73-15.08-13.21-14.27-5.96
Upgrade
Unlevered Free Cash Flow
-35.55-29.73-15.08-13.21-14.27-5.96
Upgrade
Change in Working Capital
0.2-1.05-0.984.21-0.060.08
Upgrade
Updated Aug 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q